These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2458219)

  • 1. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
    Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
    J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability of two oral sustained-release procainamide products.
    Baker BA; Reynolds JR; Gleckel L; A'Zary E; Bodenheimer MM
    Clin Pharm; 1988 Feb; 7(2):135-8. PubMed ID: 3349748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia].
    Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; Romański B
    Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 11. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative electrophysiologic effects of intravenous and oral procainamide in patients with sustained ventricular arrhythmias.
    Marchlinski FE; Buxton AE; Vassallo JA; Waxman HL; Cassidy DM; Doherty JU; Josephson ME
    J Am Coll Cardiol; 1984 Dec; 4(6):1247-54. PubMed ID: 6209319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring.
    Bauer GE; Mitchell AS; Bates F; Hellestrand K
    Med J Aust; 1977 Nov; 2(22):733-5. PubMed ID: 347229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.
    Sonnhag C; Karlsson E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procainamide in the dog: antiarrhythmic plasma concentrations after intravenous administration.
    Papich MG; Davis LE; Davis CA
    J Vet Pharmacol Ther; 1986 Dec; 9(4):359-69. PubMed ID: 3806778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of a sustained release procainamide preparation.
    Flanagan AD
    Angiology; 1982 Feb; 33(2):71-7. PubMed ID: 7039427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
    DiPersio DM; Chow MS
    Clin Pharm; 1985; 4(2):186-91. PubMed ID: 3987218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.